Huazhong University of Science and Technology Licenses Human-Derived Heart Valve Technology for RMB 20 Million
Recently, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology“Cellularized Biomaterial Inventions and Related Technologies for Their Applications”Released the public notice on cash rewards for the transformation of scientific and technological achievements. According to the notice, this technology will be20 million yuan plus sales commissiontransferred to a medical device company in Beijing, with the amount received this time being 1 million yuan; the relevant cash rewards will be distributed to key contributors.
According to the public disclosure, the transaction involves 15 intellectual property rights, including 11 Chinese invention patents, 3 Chinese utility model patents, and 1 U.S. patent, which were jointly developed by the cardiovascular research team at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
The team comprises several expert professors with profound expertise in the treatment of cardiovascular diseases and regenerative medicine. Lead ExpertDong NianguoAs a leading expert in the field of cardiovascular surgery in China and a Level-2 Professor, he currently serves as the Director of the Department of Cardiac and Great Vessel Surgery and the Director of the Cardiovascular Disease Research Institute at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. He has long been dedicated to basic research and clinical practice in valvular heart disease. As the Chief Scientist, he has presided over 12 national-level major/key projects, including the National High-Tech Research and Development Program (“863 Program”), the “12th Five-Year” National Science and Technology Support Program, the National Key R&D Program, and key projects funded by the National Natural Science Foundation of China. He holds 30 patents as the primary inventor and has served as the primary contributorAwarded the Second Prize of the National Science and Technology Progress Award。
Other members focus on fields such as tissue engineering, biomaterials development, and medical device innovation, dedicated to translating the latest research findings into practical healthcare products and services.
This patent portfolio falls within the interdisciplinary field of high-end medical devices and regenerative medicine, specifically involving the design, preparation, and clinical performance evaluation of a novel heart valve material. Its core technology revolves aroundDecellularized Heart Valve (DHV)Expanded, it is endowed with anti-calcification, anti-thrombogenic, pro-endothelialization, and in vivo regeneration capabilities through chemical modification or drug coating, thereby addressing the limitations of existing heart valve substitutes. In particular, the self-expanding nitinol alloy large-cell stent structure employed, combined with a supra-annular valve design made from porcine pericardial tissue, not only facilitates transcatheter delivery but also significantly enhances radial support and effectively prevents paravalvular leakage, providing patients with a safer and more effective treatment option.
Furthermore, to ensure the smooth transition of this series of advanced valve products from the R&D phase to clinical application, the team has also developed various supporting devices and technologies, including valve loaders, transport containers, and in vitro dynamic culture platforms. This has established a comprehensive technical system covering the entire chain of R&D, production, and application, providing robust technical support for the personalized and precise treatment of heart valve diseases.
Valvular heart disease is a condition characterized by stenosis and/or regurgitation of the cardiac valves caused by various etiologies, representing a cardiovascular disease with high morbidity and mortality rates. There are approximately 209 million patients worldwide, while the number of prevalent cases in China hasOver 25 million. This disease causes pathological changes in the heart, leading to symptoms such as exertional dyspnea, fatigue, and reduced exercise tolerance; in severe cases, it can even be life-threatening. With the intensifying trend of population aging, its incidence continues to rise year by year.
In clinical treatment,Valve Replacement Surgeryis the most core approach. It is estimated that by 2050, the global annual demand for valve replacements will reach 850,000 units. Currently, mainstream valve replacement products are primarily divided into two major categories:One type is the mechanical valve, and the other is the bioprosthetic valve.
Mechanical heart valves simulate valvular function through artificial mechanical structures, whereas bioprosthetic valves are typically fabricated from specially treated animal-derived tissues, such as porcine aortic valves and bovine pericardium. In addition, there are derivative products including tissue-engineered valve scaffolds like decellularized valves, and transcatheter heart valve prostheses implanted via catheter-based interventions.
Although mechanical valves offer superior durability, patients require lifelong anticoagulation therapy. This not only increases the risks of hemorrhage and thromboembolism but also generates significant noise during valve opening and closing, severely impacting quality of life. While bioprosthetic valves do not require long-term anticoagulation, they are prone to calcific degeneration, with an average lifespan of only 10–15 years, often necessitating reoperation. This is particularly challenging for pediatric patients, as the valves cannot adapt autonomously to somatic growth and development, making multiple surgeries unavoidable.
Currently, bioprosthetic valves are predominantly derived from animal sources. Following the implantation of acellular valves alone, the lack of effective coverage by host endothelial cells makes the surface prone to plasma protein adsorption, which in turn promotes platelet and leukocyte adhesion and activation, thereby increasing the risk of thrombosis and embolism. This not only impairs valve function but also hinders the process of valve remodeling and regeneration.
In contrast, human-derived biological valves are sourced from human tissues or constructed through induced differentiation of human cells, thereby offering greater compatibility with human tissues and a lower risk of immune rejection. Furthermore, human-derived valves facilitate more precise anatomical matching with native structures and theoretically possess regenerative potential to grow and repair alongside the human body.
However, in the process of technical implementation,The development of human-derived heart valves faces multiple technical bottlenecks:
First, the acquisition of seed cells presents challenges.Traditional methods for extracting autologous vascular endothelial cells from recipients cause damage to the recipient’s blood vessels and exhibit poor cell proliferative capacity, making it difficult to meet the scale required for clinical applications. Furthermore, the induction and differentiation efficiency of bone marrow mesenchymal stem cells is extremely low, failing to provide a stable and sufficient supply of seed cells.
Second, the integration of cells with the scaffold was suboptimal.In vitro static seeding and culture result in uneven cell distribution and loose attachment to the scaffold, making the cells prone to being washed away by bodily fluid circulation after implantation, thereby hindering the formation of an intact functional cell layer.
Again, the valve material performance is insufficient.Currently, the industry lacks materials that combine good blood compatibility, anti-calcification, anti-thrombosis, and support for in vivo remodeling and regeneration, and it is difficult to construct complex three-dimensional structures consistent with natural valves.
Finally, cell culture and experimental techniques are limited.Valves exhibit significant anisotropy and have irregular, uneven surfaces, making it difficult to create standardized experimental environments for cell migration studies. Furthermore, the lack of compatible dynamic culture equipment prevents the simulation of the in vivo human environment, thereby hindering stable cell culture.
Precisely. For the human-derived heart valves undergoing translation in this instance, the team needs toEstablished a comprehensive technical system encompassing seed cell preparation, valve material modification, and the development of culture equipment and clinical auxiliary devices.only by successfully addressing the core pain points of traditional valve substitutes: anticoagulation dependence, susceptibility to calcification and degeneration, and inability to grow autonomously.
Meanwhile, this technology has overcome technical bottlenecks in the development of human-derived heart valves, including difficulties in obtaining seed cells, poor integration between cells and scaffolds, and insufficient biocompatibility of materials, thereby providing a safer, more durable, and better-adapted solution for the treatment of valvular heart disease.
This technological achievement has established multiple core advantages in technical innovation, product performance, and patent layout, thereby constructing a comprehensive technical barrier.
In the field of technological innovation,Cell preparation technologies have achieved significant breakthroughs. The innovatively developed protocol for the directed differentiation of pluripotent stem cells, followed by magnetic bead-based sorting, yields a double-positive cell purity as high as 99.4%, effectively addressing the challenges of difficult acquisition and limited scalability of seed cells. Furthermore, leveraging lentivirus-mediated immortalization technology, valve interstitial cells can be continuously passaged for over 40 generations, eliminating the need for repeated human tissue extraction and thereby substantially reducing research costs.
In terms of material modification techniquesSignificant progress has also been achieved. Innovative anti-calcification strategies, including decellularized heart valves modified with copper ions and GDF11, as well as layer-by-layer self-assembly of polydopamine-chitosan-itaconic acid, along with low-toxicity modification techniques using nucleoside dialdehydes as substitutes for glutaraldehyde, have addressed the challenge of bioprosthetic valve calcification and degeneration at its source. Furthermore, a nanoparticle drug delivery system based on bioorthogonal reactions enables targeted delivery of anti-calcification agents, significantly reducing systemic side effects.
In terms of culture and experimental equipment,The innovatively developed dynamic pressure cell seeder ensures uniform cell seeding and deep penetration into the scaffold interior through precise pressurization at 80–120 mmHg combined with vertical rotation culture.3D Heart Valve Organoid CultivatorBy combining a dual-chamber design with microporous semipermeable membranes and perforated support plates, a three-layer “endothelial–mesenchymal–endothelial” structure was successfully constructed, effectively preventing apoptosis. Furthermore, the cell migration assay device incorporates elastic contact pads and anti-adhesion plates, addressing issues of irregular scratches on the valve surface and suspension leakage, thereby significantly enhancing experimental precision.
In terms of product advantages,Modified bioprosthetic valves possess triple properties of anti-thrombosis, anti-calcification, and endothelialization promotion. In vivo experimental results show no obvious calcified nodules, and their mechanical properties are highly matched with those of native valves. Tissue-engineered valves can achieve autonomous remodeling and regeneration, which is particularly suitable for the growth needs of pediatric patients, effectively avoiding secondary surgeries.
Furthermore,The product's safety and compatibility have been significantly improved.The use of seed cells derived from patient-specific induced pluripotent stem cells (iPSCs) significantly reduces the risk of immune rejection. Biocompatible materials such as polyurethane and poly(lactic-co-glycolic acid) were selected for valve modification. Cytotoxicity assays demonstrated high cell viability, and no significant inflammatory response was observed following in vivo implantation.
In terms of operational convenience,The product is tailored to clinical scenarios, with supporting developments such as a tablet-based flow reaction chamber, valve loader, and loading assistance devices, achieving seamless integration from dynamic culture to clinical implantation. The valve stent features a self-expanding large-cell structure, facilitating easier coronary access, while the design of positioning clips and sealing sleeves effectively reduces the risk of paravalvular leakage.
In terms of patent layout,Fifteen patents have established a comprehensive protection system encompassing “cell preparation—material modification—equipment development—clinical application,” covering core aspects such as stem cell differentiation, valve modification, culture instruments, and auxiliary devices, with no technological gaps. Meanwhile, the company holds Chinese invention patents, utility model patents, and U.S. patents. Among these, the U.S. patent focuses on decellularized valve composite materials, laying a solid foundation for the international promotion of the technology and further expanding market coverage.
Diversified protection dimensions encompass core technology patents, such as cell differentiation methods and material preparation processes, as well as utility model patents for practical devices like culture chambers and loaders. Furthermore, it covers key functional improvements, including anti-calcification and targeted drug delivery, thereby establishing multi-dimensional technical barriers that are difficult to replace.
The treatment of valvular heart disease is undergoing a technological revolution, shifting from "inert replacement" to "active regeneration."Based on our limited search capabilities, we have not yet identified any commercially available, fully humanized tissue-engineered heart valves with in vivo growth and remodeling capabilities worldwide; however, leading research teams and startups in multiple countries have entered the critical stage of clinical translation.
In China,In addition to the R&D team at Huazhong University of Science and Technology, institutions such as Fuwai Hospital of the Chinese Academy of Medical Sciences and Zhejiang University are also conducting systematic research in areas including biomaterial modification, directed differentiation of stem cells, and valve organoid models.
Internationally,Dutch-French Jointly FoundedXeltisin a leading position. Its development based on absorbable polymer materials (PEUU)Cell-free TEHV Products, by guiding natural host cell infiltration and tissue remodeling post-implantation, it has successfully completed the world’s first pediatric implantation (2022) and is continuing to advance Phase I/II clinical trials (NCT04983776), with preliminary data demonstrating favorable safety and tissue regeneration potential.
Foldax, Inc.an alternative approach is adopted, utilizing recombinant human collagen and synthetic polymers to construct non-glutaraldehyde-crosslinked“TissueForm™” Bioprosthetic Valve, received FDA “Breakthrough Device” designation; although it still falls within the category of bioprosthetic valves, its humanized material design significantly enhances anti-calcification properties and durability.
Furthermore, academic institutions such as Boston Children’s Hospital of Harvard Medical School, Eindhoven University of Technology in the Netherlands, and the University of Zurich in Switzerland have continued to produce cutting-edge findings in areas including autologous stem cell seeding, dynamic bioreactor culture, and 3D biomimetic printing, thereby providing theoretical support for the long-term functional stability of tissue-engineered heart valves (TEHVs).
Despite ongoing challenges, the convergence of materials science, stem cell technology, and regenerative medicine is steadily advancing next-generation “living” heart valves from the laboratory to clinical practice. This progress holds promise for delivering a definitive therapeutic solution within the next decade to millions of patients with valvular heart disease, particularly children, offering valves that can grow with the patient and eliminate the need for repeated surgeries.